GENTEX CORP (NASDAQ:GNTX) Q3 2025 Earnings Fall Short of Estimates Gentex (GNTX) Q3 2025 earnings miss analyst estimates on EPS and revenue. Shares fell as regional challenges in Europe and China impacted results, despite improved gross margins.
US Stocks Hit New Highs As Magnificent Seven Reach $19 Trillion: What's Moving Markets Friday? Wall Street looked set to close the week on a high note, with large-cap benchmarks pushing higher in Friday's midday trading as optimism over corporate earnings and progress on global trade talks provided support for risk assets.
Why Gentex Stock Is Gaining Today? Gentex shares jumped 15% after beating Q2 estimates, boosting full-year sales guidance, and posting strong margins despite weak auto production.
Gapping stocks in Friday's session Traders are paying attention to the gapping stocks in Friday's session. Let's dive into which stocks are experiencing notable gaps.
Gentex Corp (NASDAQ:GNTX) Surpasses Q2 2025 Earnings Estimates, Sparks 11% Pre-Market Rally Gentex Corp (GNTX) beats Q2 2025 earnings with $657.9M revenue and $0.47 EPS, sparking an 11% pre-market rally. Strong automotive and tech growth fuels investor optimism.
Gentex Q1 Impacted By Tariff Uncertainty, Suspends Mirror Production For Chinese Market Gentex shares fall as Q1 results reflect tariff pressures, prompting a halt in China-bound mirror production and a lowered 2025 sales outlook.
15 Undervalued Consumer Discretionary Stocks For 2024 A look at 15 consumer discretionary stocks that look reasonably valued.
Gentex's Q3 Performance Defies Auto Industry Headwinds, Trims 2024 Outlook Gentex Corporation's Q3 earnings beat estimates with a 53-cent EPS and $608.53 million in revenue, driving stock gain.
Jim Cramer: Viking Therapeutics Has 'Many Ships Coming In' Viking Therapeutics received an Overweight rating and a December 2025 price target of $80 from JPMorgan analysts.
